11 out of the 12 analysts who have coverage on Eris Lifesciences have a “buy” rating on the stock, while the other one has a “hold” rating.
11 out of the 12 analysts who have coverage on Eris Lifesciences have a “buy” rating on the stock, while the other one has a “hold” rating.